Zobrazeno 1 - 10
of 265
pro vyhledávání: '"Kimberly L Blackwell"'
Autor:
John H. Strickler, Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, Michael A. Morse, David Z. Chang, James L. Wells, Kimberly L. Blackwell, P. Kelly Marcom, Christy Arrowood, Emily Bolch, Sherri Haley, Fatima A. Rangwala, Ace J. Hatch, Andrew B. Nixon, Herbert I. Hurwitz
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended ph
Externí odkaz:
https://doaj.org/article/cee4dcf4fc8d4276878e7ac77b99ef23
Autor:
Li Zhu, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, Rim Kim, Katherine Pogue-Geile, Sarah Sammons, Naema Nayyar, Ugonma Chukwueke, Priscilla K. Brastianos, Carey K. Anders, Adam C. Soloff, Dario A. A. Vignali, George C. Tseng, Leisha A. Emens, Peter C. Lucas, Kimberly L. Blackwell, Steffi Oesterreich, Adrian V. Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Abstract The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast cancer lesions remaining largely und
Externí odkaz:
https://doaj.org/article/c2fc89921000427ea6b01395b0309364
Autor:
Kimberly L. Blackwell, Sarah Bacus, Renee A. Welch, Erika Hamilton, Justin Favaro, Gretchen G. Kimmick, Judith Hopkins, P. Kelly Marcom, Bercedis L. Peterson, Vijaya Chadaram, Christina I. Herold
XLS file - 16K, Pulmonary and pleural effusions, pneumonitis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5bf3beb80e1a37fabde4ae5b4ab567b
https://doi.org/10.1158/1078-0432.22444086
https://doi.org/10.1158/1078-0432.22444086
Autor:
Kimberly L. Blackwell, Sarah Bacus, Renee A. Welch, Erika Hamilton, Justin Favaro, Gretchen G. Kimmick, Judith Hopkins, P. Kelly Marcom, Bercedis L. Peterson, Vijaya Chadaram, Christina I. Herold
Purpose: A phase II study of dasatinib, an inhibitor of multiple oncogenic tyrosine kinases including Src, was conducted to evaluate 16-week progression-free rate and tolerability in patients with previously treated metastatic breast cancer (MBC). Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35626b66f610a4abdadbd2105d7447df
https://doi.org/10.1158/1078-0432.c.6520056
https://doi.org/10.1158/1078-0432.c.6520056
Autor:
Rebecca G. Bagley, Denise A. Yardley, Volker Möbus, Abdel-Baset Halim, Rita Nanda, Gail S. Wright, Andres Forero-Torres, Thomas Hawthorne, Javier Cortes, Alberto J. Montero, Linda T. Vahdat, Kimberly L. Blackwell, Michelle E. Melisko, Melinda L. Telli, Yi He, Peter Schmid, Cynthia X. Ma, Christopher D. Turner
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Scientia
NPJ Breast Cancer
Scientia
NPJ Breast Cancer
Breast cancer; Cancer Càncer de mama; Càncer Cáncer de mama; Cáncer The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ba4d4292b16f0be2f40ca88020f4d3
https://doaj.org/article/17180d15d53a444b97cb83ce78fb7480
https://doaj.org/article/17180d15d53a444b97cb83ce78fb7480
Autor:
Nike Beaubier, Aneta Piwowarczyk, Minetta C. Liu, Jeff Schaffer, Kimberly L. Blackwell, Ben Park
Publikováno v:
Cancer Research. 81:PD9-12
Genomic testing has transformed clinical care in metastatic breast cancer. Cell-free DNA (cfDNA) has made sequential testing feasible, however, concordance between tissue and cfDNA, sensitivity of cfDNA, and optimal sampling frequency have not been e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea84b32ec016ebfce659d9072dd595f9
https://doi.org/10.1158/1538-7445.sabcs20-pd9-12
https://doi.org/10.1158/1538-7445.sabcs20-pd9-12
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
Autor:
Timothy A. Yap, Arya Ashok, Jessica Stoll, Elizabeth Mauer, Vanessa M. Nepomuceno, Kimberly L. Blackwell, Judy E. Garber, Funda Meric-Bernstam
Publikováno v:
JAMA network open. 5(5)
Germline testing guidelines are suggested for specific disease types or a family history of cancer, yet alterations are found in cancer types in which germline testing is not routinely indicated. The clinical role of identifying germline variants in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4511d3bcf2f40d7d167cfa6187c5b54
https://pubmed.ncbi.nlm.nih.gov/35594050
https://pubmed.ncbi.nlm.nih.gov/35594050
Autor:
Matthew MacKay, Joshua Drews, Bonnie V. Dougherty, Duane Hassane, Chris Mason, Gaurav Khullar, Calvin Chao, Joel Dudley, Kimberly L. Blackwell, Nike T. Beaubier, Justin Guinney
Publikováno v:
Cancer Research. 82:62-62
Background: Actionable genomic alterations can be identified through either a biopsy of solid tissue or the detection of circulating tumor DNA from plasma. Little is known about the concordance rates of pathogenic variants between cell free DNA (cfDN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33b813983614f72efacd2f5ed66e0577
https://doi.org/10.1158/1538-7445.am2022-62
https://doi.org/10.1158/1538-7445.am2022-62
Autor:
Minetta C. Liu, Matthew MacKay, Matthew Kase, Aneta Piwowarczyk, Christine Lo, Jeff Schaeffer, Justin D. Finkle, Christopher E. Mason, Nike Beaubier, Kimberly L. Blackwell, Ben Ho Park
Publikováno v:
JCO precision oncology. 6(1)
PURPOSE Tissue-based next-generation sequencing (NGS) in metastatic breast cancer (mBC) is limited by the inability to noninvasively track tumor evolution. Cell-free DNA (cfDNA) NGS has made sequential testing feasible; however, the relationship betw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc590eed5a186aa9560aad7496027350
https://pubmed.ncbi.nlm.nih.gov/35721584
https://pubmed.ncbi.nlm.nih.gov/35721584
Autor:
Ace J. Hatch, Christel Rushing, Emily Bolch, Hope E. Uronis, S. David Hsu, James Leroy Wells, Abigail B. McLeod, Donna Niedzwiecki, Christy Arrowood, Kimberly L. Blackwell, John H. Strickler, P. Kelly Marcom, S. Yousuf Zafar, Michael A. Morse, Herbert Hurwitz, Ivy Altomare, Sherri Haley, Andrew B. Nixon, Fatima A. Rangwala, David Z. Chang
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
BMC Cancer
Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::544ae352d7f5233576a777ba7b6f4aa4
http://link.springer.com/article/10.1186/s12885-019-6234-8
http://link.springer.com/article/10.1186/s12885-019-6234-8